Spark Therapeutics Inc. (NASDAQ:ONCE) shot up 2.5% on Thursday . The company traded as high as $54.49 and last traded at $53.24, with a volume of 257,140 shares. The stock had previously closed at $51.95.

A number of brokerages have weighed in on ONCE. Jefferies Group began coverage on shares of Spark Therapeutics in a report on Thursday, June 2nd. They issued a “hold” rating on the stock. Cantor Fitzgerald assumed coverage on shares of Spark Therapeutics in a report on Thursday, June 2nd. They set a “buy” rating and a $100.00 price target on the stock. Wedbush reiterated an “underperform” rating and set a $29.00 price target on shares of Spark Therapeutics in a report on Monday, June 13th. SunTrust Banks Inc. increased their price target on shares of Spark Therapeutics from $64.00 to $72.00 and gave the company a “buy” rating in a report on Tuesday, June 21st. Finally, Cowen and Company reiterated a “buy” rating and set a $75.00 price target on shares of Spark Therapeutics in a report on Thursday, May 19th. Three research analysts have rated the stock with a sell rating, four have assigned a hold rating and six have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $58.56.

The firm’s 50-day moving average price is $50.82 and its 200 day moving average price is $38.05. The company’s market cap is $1.48 billion.

Spark Therapeutics (NASDAQ:ONCE) last released its earnings results on Wednesday, May 4th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.84) by $0.11. The business had revenue of $1.29 million for the quarter, compared to the consensus estimate of $1.48 million. The company’s quarterly revenue was down 43.2% on a year-over-year basis. Analysts expect that Spark Therapeutics Inc. will post ($3.92) EPS for the current year.

In other Spark Therapeutics news, CEO Jeffrey D. Marrazzo sold 25,000 shares of the business’s stock in a transaction that occurred on Thursday, May 19th. The shares were sold at an average price of $46.01, for a total transaction of $1,150,250.00. Following the sale, the chief executive officer now owns 255,000 shares of the company’s stock, valued at approximately $11,732,550. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Barge Joseph La sold 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 5th. The stock was sold at an average price of $52.24, for a total transaction of $156,720.00. Following the sale, the insider now directly owns 8,325 shares in the company, valued at approximately $434,898. The disclosure for this sale can be found here.

Other hedge funds recently added to or reduced their stakes in the company. CAM Group Holding A S increased its stake in Spark Therapeutics by 1.8% in the fourth quarter. CAM Group Holding A S now owns 78,620 shares of the company’s stock valued at $3,562,000 after buying an additional 1,400 shares in the last quarter. TD Asset Management Inc. increased its stake in Spark Therapeutics by 72.2% in the fourth quarter. TD Asset Management Inc. now owns 58,187 shares of the company’s stock valued at $2,636,000 after buying an additional 24,400 shares during the period. UBS Oconnor LLC acquired a new stake in Spark Therapeutics during the fourth quarter valued at approximately $4,395,000. Casdin Capital LLC acquired a new stake in Spark Therapeutics during the fourth quarter valued at approximately $6,570,000. Finally, American Century Companies Inc. increased its stake in Spark Therapeutics by 56.2% in the fourth quarter. American Century Companies Inc. now owns 419,203 shares of the company’s stock valued at $18,994,000 after buying an additional 150,817 shares during the period.

Spark Therapeutics, Inc (Spark) is engaged in developing products in the field of gene therapy. Spark’s product candidate, SPK-RPE65, which is in Phase III clinical trial stage, targets a group of rare blinding conditions known as inherited retinal dystrophies (IRDs), caused by non-sex linked or autosomal recessive mutations in the RPE65 gene.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.